Overview IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma Status: Recruiting Trial end date: 2023-06-01 Target enrollment: Participant gender: Summary A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma Phase: Phase 2 Details Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.